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Abstract
Aims—Dipeptidyl-peptidase-4 inhibitors (DPP-4i) have been implicated with an increased 
pancreatic cancer risk. We therefore compared pancreatic cancer incidence and diagnostic work-
up among initiators of DPP-4i versus sulfonylureas (SU) and thiazolidinediones (TZD).
Methods—Medicare claims data were examined in a new-user active-comparator cohort study. 
Patients >65 years with no prescriptions for DPP-4i, SU or TZD at baseline were included if they 
had at least two claims for the same drug within 180 days. Using an as-treated approach and 
propensity score-adjusted Cox models, we estimated hazard ratios (HR) and 95% confidence 
intervals (CI) for pancreatic cancer. Diagnostic work-up was compared using risk ratios (RR).
RESULTS—In the DPP-4i vs SU comparison, there were 18,179 DPP4i initiators of which 26 
developed pancreatic cancer (follow-up time interquartile range 5–18 months). In the DPP-4i vs 
TZD comparison there were 29,366 DPP-4i initiators and 52 developed pancreatic cancer. The 
hazard of pancreatic cancer with DPP-4i was lower relative to SU (HR=0.6, CI 0.4–0.9) and 
similar to TZD (HR=1.0, CI 0.7–1.4). Excluding first 6 months of follow-up to reduce the 
potential for reverse causality did not alter results. Probability of diagnostic work-up post-
initiation among DPP-4i initiators (79.3%) was similar to TZD (74.1%) (RR=1.06, CI 1.05–1.07) 
and SU (74.6%) (RR=1.06, CI1.05–1.07). The probability of diagnostic workup pre-index was 
~80% for all cohorts.
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Conclusion—Though limited by sample size and the observed duration of treatment in the US, 
our well-controlled population based study suggests no increased short-term pancreatic cancer risk 
with DPP-4i relative to SU or TZD.
Introduction
Dipeptidyl-peptidase-4 inhibitors (DPP-4i) were introduced in the United States in 2006 to 
improve glycemic control in adults with type 2 diabetes. Sitagliptin was the first in class, 
followed by saxagliptin (2008), linagliptin (2011) and alogliptin (2012).[1] There is 
considerable interest in these drugs due to their tolerability (apart from nasopharyngitis), 
body-weight neutrality and ease of use [1,2], but only limited data are available on their 
safety. In 2009, the Food and Drug Administration (FDA) issued a safety communication 
regarding post-marketing reports of acute pancreatitis in patients using sitagliptin or 
sitagliptin/metformin.[3] Subsequently, manufacturers of these drugs revised the labels to 
include information regarding reports of acute pancreatitis, recommending that their use be 
promptly discontinued if pancreatitis was suspected while using these products.[3–5] In 
2011, an analysis of the FDA Adverse Events Reporting System (FAERS) demonstrated 
increased rates of pancreatitis and pancreatic cancer with incretin-mimetics compared to 
other antihyperglycemic therapies. Pancreatic cancer rate with sitagliptin was found to be 
2.7 times the rate in the control group, raising concern about a potential adverse effect.[6] 
The FAERS analysis has been criticized mainly due to the limitations of the FAERS 
database; including the lack of denominator, disproportionate reporting, confounding and 
inconsistencies in exposure and outcome ascertainment.[7,8] In March 2013, Butler et al [9] 
examined pancreata from brain-dead organ donors and found increased pancreatic mass, 
exocrine cell proliferation and dysplasia in organ donors treated with incretin-mimetics (7 
sitagliptin, 1 exenatide) compared with diabetic patients on other antihyperglycemic agents 
and non-diabetic controls. The authors suggested that these observations are compatible with 
an increased pancreatic cancer risk in those treated with incretin-mimetics.[9] However, this 
study is limited by small numbers (n=34), poor matching on baseline characteristics and 
absence of information about treatment duration.[10] Following this, the FDA issued a drug 
safety communication announcing that it is evaluating such reports but that it had “not 
reached any new conclusions about safety risks with incretin-mimetics”.[11] Recently two 
trials (SAVOR-TIMI 53 and EXAMINE) evaluating the cardiovascular effects of DPP-4i 
were reported. [12,13] The SAVOR-TIMI compared saxagliptin versus placebo over median 
2.1 years follow-up and evaluated pancreatic cancer as a safety outcome but found no 
indication for an increased risk (5 events with saxagliptin versus 12 with placebo).[12] The 
EXAMINE trial comparing alogliptin versus placebo found no reports of pancreatic cancer 
over about 1.5 years of median follow-up in 5380 patients.[13]
There have been many pharmacoepidemiologic studies examining acute pancreatitis with 
DPP-4i [14–16], but none on pancreatic cancer. We therefore compared the pancreatic 
cancer incidence after initiation of DPP-4i versus sulfonylureas (SU) and thiazolidinediones 
(TZD) using 2006–2011 Medicare claims data which reflect the diabetes burden and 
treatment in older adults. We conducted this study despite the limited timeframe of available 
Medicare Part D data on dispensed drugs because of the imperative of conducting well-
controlled studies in light of the hypothesis generated in relatively uncontrolled studies as 
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treatment decisions are being made on a daily basis. While not intended to be definitive, the 
data presented are the first to examine a well-defined high-risk population, using the state-
of-the-art new-user active-comparator study design, rigorous confounding control, and 
various sensitivity analyses.
Methods
The study was reviewed and approved by the University of North Carolina Chapel Hill 
Institutional Review Board (IRB # 12-1466). Before scrutinizing the data or conducting 
analyses, the study protocol was registered in the European Network of Centers for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP) electronic register of studies 
(http://www.encepp.eu/encepp/viewResource.htm?id=3411).
Study population
We conducted a new-user active-comparator cohort study using a 20% random sample of 
Medicare beneficiaries >65 years with fee-for-service Part A (hospital coverage), B 
(outpatient care) and D (dispensed prescription drugs) enrollment in at least one month 
during a calendar year from January 1, 2007 (2006 for Part A and B) to December 31, 2011. 
Medicare is the largest public health insurance program in the US, covering >98% of adults 
65 years or older.[17] This data contains information about demographics, enrollment, 
diagnoses, procedures and prescription drugs for each enrollee.[17]
From this population, we identified two new-user active-comparator cohort pairs 
(supplementary figures 1,2) mimicking a clinical treatment decision: 1. initiators of DPP-4i 
versus SU (not exposed to DPP-4i or SU in the previous 6 months) and 2. initiators of 
DPP-4i versus TZD (not exposed to DPP-4i or TZD in the previous 6 months). Prevalent 
users in the 6 months before initiation were excluded (example, in the DPP-4i vs SU 
comparison, patients could be on any antihyperglycemic drugs other than DPP-4i and SU in 
the 6 months pre-initiation). A DPP-4i initiator with no previous prescription of SU and 
TZD would be eligible for inclusion in both comparisons (DPP-4i vs SU and DPP-4i vs 
TZD). Since the drugs of interest are indicated for diabetes management, patients were not 
required to have a diabetes claim for cohort inclusion. Drug initiation was defined as the 
first prescription of the drug with the index date defined as the date of dispensing. Patients 
needed to have at least 6 months of continuous Part D enrollment and at least 12 months 
parts A and B enrollment pre-index. To ensure that patients were actually started on the 
drugs, we restricted our cohorts to patients with a second prescription for the same drug 
dispensed within 6 months after the index prescription and follow-up started from the 
second fill date. Finally, using a sensitive definition of ICD-9-CM codes and procedure 
codes (Supplemental table 1), we excluded patients with evidence of cancer or cancer-
related procedures any time before the start of follow-up.
Outcome
The outcome was incident pancreatic cancer defined as at least two inpatient or outpatient 
claims with ICD-9-CM codes 157.xx within two months.[18] This definition has been 
shown to have high specificity (minimize false positives, yield unbiased relative risk 
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estimates) for other cancers in a Medicare population.[18] We analyzed the data using both 
as-treated (preferred in studies of adverse outcomes) and an intent-to-treat approach 
(preferred here because the induction period for pancreatic cancer is thought to be long). In 
the as-treated analysis, patients were followed up from the second prescription until: the 
outcome, discontinuation (no new prescription for the initiated drug, within days-supply plus 
a 180 days grace period to allow for dose adjustment/irregular use), switching or 
augmentation with the comparator drug, death, end of enrollment, or December 31, 2011. In 
the intent-to-treat approach patients were not censored when they stopped/switched/
augmented therapy, but were followed until the outcome occurred, death, end of enrollment, 
or December 31, 2011. Patients with a diagnosis of any non-pancreatic cancer (except non-
melanoma skin cancer) during follow-up were censored at that point since diagnostic-work-
up or treatment of other cancers may affect the incidence of pancreatic cancer.
Confounding control and analysis
We estimated propensity scores using a number of baseline variables. Comorbidities and 
health care utilization were assessed during the 12 months pre-index and use of other drugs 
was assessed during the 6 months pre-index. Using these variables, we predicted the 
probability for initiating DPP-4i versus SU and DPP-4i versus TZD for each patient (the 
propensity score) using two separate logistic regression models.[19] We implemented the 
estimated propensity scores using weights that led to the “standardization” of covariates in 
the SU and TZD groups to the covariate distribution observed in DPP-4i initiators. This was 
achieved by assigning a weight of 1 to the treated (DPP-4i) and a weight of (propensity 
score/(1-propensity score)) to SU and TZD.[20] This weighting creates pseudo-populations 
of SU and TZD initiators with similar covariate distribution as in DPP-4i initiators. This 
covariate balance across groups allows us to estimate the unconfounded treatment effect in a 
population of patients similar to those actually initiating DPP-4i.[20, 21] Our weighted 
analysis thus answers the question “what would have happened to patients who initiated 
DPP-4i if they had initiated SU or TZD, instead”.[22]
After checking covariate balance in the pseudo-populations we computed weighted Kaplan 
Meier plots to check the proportional hazards assumption. We then fit Cox proportional 
hazards models in the weighted pseudo-populations with treatment as the only independent 
variable to compare pancreatic cancer incidence among initiators of DPP-4i vs SU and 
DPP-4i vs TZD.
Diagnostic procedures
Studies assessing cancer risk after a new diabetes diagnosis have raised concerns about 
differential cancer detection biasing the association between diabetes and cancer.[23, 24] 
The potential for detection bias also presents methodological challenges in studies assessing 
cancer risk with antihyperglycemic drugs. It is possible that patients initiating DPP-4i may 
undergo increased diagnostic screening just before and after drug initiation, which may lead 
to increased discovery of pancreatic cancer in the DPP-4i group relative to SU/TZD. To 
address this we compared the use of diagnostic procedures (Supplemental table 2) in 6 
months before and after the index date among initiators of DPP-4i versus SU and TZD using 
risk ratios and 95% confidence intervals.
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We conducted sensitivity analyses using a 6 month induction period (excluding first 6 
months of follow-up). This was done in order to reduce the potential for a spurious drug-
pancreatic cancer association due to pre-clinical pancreatic cancer leading to hyperglycemia 
and initiation of antihyperglycemic therapy (reversed causality).[25, 26] Bias resulting from 
reversed causality would be strongest immediately following treatment initiation. Second, 
we compared the pancreatic cancer incidence in DPP-4i initiators versus a combined 
comparison group of SU and TZD initiators.
Results
Tables 1 and 2 present the baseline covariates for each comparison. DPP-4i initiators had a 
mean age ~75 years and ~35% were men. Compared with DPP-4i initiators, SU initiators 
were more likely to be men, less likely to have connective tissue diseases, neuropathy or 
retinopathy and less likely to be on other antihyperglycemics, statins, angiotensin receptor 
blockers and beta-blockers during baseline (table 1). The SU initiators were also less likely 
to have had lipid testing and influenza vaccinations than the DPP-4i initiators. The TZD 
initiators were more likely to be men and non-white compared to the DPP-4i initiators (table 
2). The prevalence of comorbidities and use of other antihyperglycemics, antihypertensives 
(except ACE inhibitors), statins was lower in TZD compared to the DPP-4i group. TZD 
initiators were also slightly less likely to get influenza vaccinations or lipid testing. In the 
column ‘effect of channeling’, we present the multivariable effect of these covariates on 
channeling between initiating DPP-4i versus comparators. After weighting (weighted 
SU/TZD columns, tables 1,2), all covariates in the weighted SU and TZD pseudo-
populations are identical to the distribution of the DPP-4i initiators. This indicates that we 
were able to balance cohorts on all measured covariates which removes any confounding by 
these variables.
Table 3 presents incidence rates for pancreatic cancer per 100,000 person-years, time-to-
event, and the crude and adjusted (weighted) hazard ratios comparing DPP-4i with SU and 
TZD. In the as-treated analysis, based on 26 events among 18,179 DPP-4i initiators and 177 
events among 63,746 SU initiators, the adjusted HR was 0.62 (CI: 0.41, 0.94). There were 
52 pancreatic cancers among 29,366 DPP-4i initiators and 54 events among 26,332 TZD 
initiators leading to an adjusted HR of 0.97 (CI: 0.65, 1.43). Overall these results indicate no 
increased short-term hazard of pancreatic cancer with DPP-4i relative to SU, nor with 
DPP-4i relative to TZD. Using the intent-to-treat approach (table 3), the adjusted HR was 
0.68 (CI: 0.47, 1.00) for DPP-4i vs SU and 0.88 (CI: 0.62, 1.23) for DPP4i vs TZD. As 
shown in figure 1, similar relations were observed in those on drugs for a longer time. 
Figure 2 presents results stratified by duration of use since initiation. Based on a total of 53 
events among 6,994 DPP-4i and 31,603 SU initiators on therapy for one year or more, we 
found no indication of an increased pancreatic cancer incidence with DPP-4i (HR=0.68, CI: 
0.28, 1.61). In the DPP-4i versus TZD comparison, there were 11,768 DPP-4i and 12,690 
TZD initiators on treatment for one year or more and the hazard ratio of pancreatic cancer 
based on 22 events was 0.62 (0.26, 1.51).
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To reduce the potential of reverse causality, we repeated the as-treated analyses excluding 
the first 6 months of follow-up. In the DPP-4i vs SU comparison, this yielded 12,332 
DPP-4i and 49,265 SU initiators and a total of 100 pancreatic cancers resulting in an 
adjusted hazard ratio of 0.73 (CI: 0.40, 1.32). In the DPP-4i vs TZD comparison, there were 
21,020 DPP-4i and 21,562 TZD initiators and 51 pancreatic cancers with an adjusted hazard 
ratio of 0.71 (CI: 0.40, 1.25).
We also compared DPP-4i initiators with a combined group of SU or TZD initiators such 
that no patient had a prescription of any of these three drugs in the 6 months pre-initiation. 
Using an as-treated approach, this yielded 17,166 DPP-4i initiators and 69,729 initiators of 
SU/TZD and an adjusted hazard ratio of 0.71 (CI: 0.47, 1.08) indicating no increased 
pancreatic cancer incidence with DPP-4i relative to SU and TZD combined.
We did not find any difference in the risk of diagnostic work-up in the 6 months before and 
after drug initiation (Supplemental table 3). We performed this analysis to address the 
potential for increased diagnostic work-up in DPP-4i that could bias towards a higher 
incidence due to diagnosing some preclinical pancreatic cancers. In the 6 months post-index, 
the risk of diagnostic work-up was between 74.1 to 79.3% in all groups. The probability of 
diagnostic work-up among initiators of DPP-4i was similar to SU (RR: 1.06; CI: 1.05,1.07) 
and TZD initiators (RR: 1.06; CI: 1.05,1.07). In the 6 months pre-index, the risk of 
diagnostic work-up was similar in all groups (81.0–86.8%).
Conclusions
We found no evidence of increased short-term pancreatic cancer incidence with DPP-4i 
versus SU or TZD in our new-user active-comparator cohort study based on a 20% random 
sample of all currently available Medicare claims. Our study is limited by the short 
treatment duration, both as a function of actual treatment dynamics (as-treated analysis – 
follow-up IQR 5–18 months, median 10 months) and the availability of data (intent-to-treat - 
IQR 6–26 months, median 14 months). However, we required the patients to have two 
prescriptions of the same drug and started follow-up from the second prescription. The mean 
(median) time between the two prescriptions was approximately 1.5 (1) months 
(Supplemental table 4) indicating that the patients were on treatment for a slightly longer 
period than reported. Our approach of excluding patients with any cancer between the first 
and the second prescription can affect generalizability of results to all patients initiating 
these drugs, but the number of patients excluded was very small (<100 in each group) so that 
this is negligible. Short follow-up is likely to be an issue for the next few years since none of 
the clinical trials are planned for >5 years and real-world treatment patterns do not allow 
long-term follow-up of patients. Given the likely long induction period for pancreatic cancer 
it may be impossible to detect differences in cancer initiation between DPP-4i and 
comparators in our study. However our approach of synchronizing patients on diabetes 
severity and baseline pancreatic cancer risk likely makes the distribution of early stage 
preclinical cancers similar in DPP-4i versus comparators and we should thus be able to 
detect a difference in cancer promotion.
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A recent meta-analysis among diabetic patients reported increased odds of pancreatic cancer 
with SU use versus non-use (although there was considerable heterogeneity across all 
studies that could not be explained by study design, setting or location), and no difference in 
odds with TZD use versus non-use.[27] Our observation of a slightly lower adjusted hazard 
of pancreatic cancer with DPP-4i versus SU could be a function of only 26 events in the 
DPP-4i group and also a potentially increased pancreatic cancer risk with SU which could 
make DPP-4i appear protective. Therefore these results should be interpreted with caution 
and additional data are needed to investigate this further. For each comparison, the results 
did not change among long term drug users as shown in figures 1 and 2.
Our results were robust to changes in analysis approaches and varying induction periods. 
We found little evidence for differential diagnostic work-up in DPP-4i initiators, indicating 
that differential outcome detection bias is less of a concern in our study.
Our results are contrary to those in the aforementioned FAERS analysis and the histologic 
study on human pancreata which suggested an increased pancreatic cancer risk with DPP-4i.
[6,9] The limitations of these studies clearly warranted further investigation using large 
population-based healthcare data and state-of-the-art non-experimental methods.
A strength of our study is the use of a new-user active-comparator cohort design which is 
analogous to a head-to-head clinical trial [28] and mimics the most relevant clinical decision 
(‘which treatment to initiate’ rather than ‘treatment or not’). It allows synchronizing follow-
up in all cohorts which is the basis for sensitivity analyses of induction periods.[28] 
Specifically, we identified initiators of DPP-4i or comparators after a 6 month washout. 
Potential confounders were measured before drug initiation thereby avoiding the problem of 
controlling for covariates potentially affected by prevalent treatment.[28] The covariate 
balance achieved by our propensity score weighting reassures us about absence of 
confounding by these covariates. Using active comparators helped balance the groups on 
diabetes severity, baseline pancreatic cancer risk (particularly important since diabetes is a 
risk factor for pancreatic cancer) and addressed confounding by indication and frailty. Given 
that many plausible predictors of treatment choice were already balanced by using an active 
comparator (before propensity score implementation), we may be more inclined to make the 
assumption that unmeasured confounding is not a major concern in our study, although we 
can never be certain about this point.
Compared to SU and TZD, DPP-4i initiators were more likely to get statins, influenza 
vaccines or blood lipids tested suggesting that DPP-4i initiators are more likely to follow 
guidelines of disease prevention, i.e., healthy users.[29] However, we successfully balanced 
the cohorts of DPP-4i and SU and TZD initiators on all these factors using weighting and 
this would tend to reduce imbalances of unmeasured factors associated with measured 
healthy user behaviors.[30]
Our study should be interpreted in the context of its limitations. As outlined above, the main 
limitation is short duration of follow-up and the results should be cautiously accepted. The 
follow-up time in the DPP-4i group was slightly shorter than the follow-up for comparators 
(supplemental table 5), but Cox models do not require equal person-time to be valid. The 
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relatively constant slope of the Kaplan-Meier plots provide some reassurance that cancer 
risk in DPP-4i initiators are not increasing in the second year; however no implications can 
be made at this time about longer periods of exposure. Our study also had limited number of 
outcomes and number of DPP-4i initiators. DPP-4i were introduced in the US only in 2006 
while SU and TZD have been on the market for a longer time, which might explain the 
small number of DPP-4i initiators as many potential candidates were excluded because of 
prior exposure to SU/TZD. Limited number of outcomes may be attributed to the fact that 
pancreatic cancer is a rare disease.[31] However, the median age at pancreatic cancer 
diagnosis is 71 years and the Medicare data is likely to have the highest power to study this 
outcome compared to other claims data from equivalent years. Based on the pancreatic 
cancer rates in the general US population reported by National Cancer Institute’s 
Surveillance Epidemiology and End Results (SEER), we calculated the expected number of 
events for our study population and compared it to the observed events in our data.[32] The 
ratio of observed to expected events was between 2–3 implying that that our study 
population had more than twice the number of pancreatic cancer events than the general US 
population, consistent with the fact that diabetic individuals have a 2-fold increased 
pancreatic cancer risk compared with the general population.[33, 34] In separate analyses 
(data not shown), we attempted to examine incident pancreatic cancer with the GLP-1 
receptor agonists. However, the sample size was even more restricted, precluding robust 
analysis. Since GLP-1 receptor agonists and DPP-4i potentiate incretin action through 
different mechanisms and the exact spectrum of adverse events is uncertain, we did not 
combine these into a single analysis.[8]
There is a possibility of reverse causality affecting our study. Patients with preclinical 
pancreatic cancer may have worsening of their diabetes leading to initiation of 
antihyperglycemic treatments. However, our results did not change even after excluding the 
first 6 months of follow-up. We would have liked to extend this to 12 months or longer but 
were limited by treatment dynamics and data availability.
Finally, we could not adequately control for potential risk factors for pancreatic cancer like 
smoking, body mass index (BMI) since they not well-measured in Medicare claims.[35–37] 
However, we used chronic obstructive pulmonary disease as a proxy for smoking and 
balanced the comparison groups on this variable. We could not statistically adjust for BMI. 
However, BMI is only weakly associated with pancreatic cancer and therefore not adjusting 
for it is not expected to affect our results.[37]
In summary, we did not find an increased short-term pancreatic cancer risk after initiation of 
DPP-4i versus SU or TZD in older diabetic patients. This study does not establish the safety 
of DPP-4i – but uses real-world treatment patterns to present the first alternate view of the 
situation in contrast to the reports of increased risk from non-population based studies with 
similar or even lesser exposure and events. Given the short follow-up, ourstudy could not 
assess long term risk and therefore physicians should cautiously interpret the results while 
using them to guide clinical decisions. Further research should continue to assess the risk as 
more data become available as recently suggested.[38–41] Meanwhile, our results will help 
prudent clinicians and patients to make reasonable treatment decisions based on the 
currently available evidence.
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Figure 1. Kaplan-Meier plots of time to event for pancreatic cancer with dipeptidyl-peptidase-4 
inhibitors (DPP-4i), sulfonylureas (SU) and thiazolidinediones (TZD)
For the graphs titled ‘DPP vs SU’ red dotted line = DPP-4i and blue solid line = SU For 
graphs titled ‘DPP vs TZD’, red dotted line = DPP-4i and blue solid line = TZD
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Figure 2. Hazard ratios and 95% CI for pancreatic cancer stratified by time since drug initiation
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